The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment. Never before was there a drug that actually worked for weight loss.